Abstracts tagged "Biomarkers and systemic lupus erythematosus (SLE)"

Abstract Number: 2248 • 2012 ACR/ARHP Annual Meeting
Serum Phosphatidylserine-Specific Phospholipase A1 (PS-PLA1) Identified As a Novel Biomarker for Systemic Lupus Erythematosus (SLE)
Tetsuji Sawada¹, Kazuhiro Nakamura², Ryunosuke Ohkawa², Aki Shoji¹, Koichiro Tahara¹, Haeru Hayashi¹, Eri Kimura¹, Koji Igarashi³, Junken Aoki⁴ and Yutaka Yatomi⁵, ¹Rheumatology, Tokyo Medical University, Tokyo, Japan, ²Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan, ³AIA Research Group, TOSOH Corporation, Kanagawa, Japan, ⁴Department of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan, ⁵Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: Lysophosphatidylserine (LPS), which is a degraded form of phosphatidylserine (PS), is an acidic lyso-glycerophospholipid, similar to lysophosphatidic acid (LPA). LPS is known to mediate…
Abstract Number: 2256 • 2012 ACR/ARHP Annual Meeting
A Population of IL-21 Producing CD4⁺ T Cells Correlates with Disease Damage in Systemic Lupus Erythematosus (SLE) Patients
Babak Noamani¹, Stacey Morrison², Dafna D. Gladman³, Jorge Sanchez-Guerrero⁴, Murray B. Urowitz⁵, Joan E. Wither⁶ and Carolina Landolt-Marticorena⁷, ¹Genetics and developmental biology, Toronto Western Research Institute, Toronto, ON, Canada, ²Div Rheumatology Rm MP-10-304, The Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴UHN Toronto Western Hospital, Toronto, ON, Canada, ⁵Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: SLE mice models implicate IL-21, a T cell-derived cytokine, in disease pathogenesis with cytokine over-expression promoting the development of auto-antibodies and lupus-like clinical syndromes.…
Abstract Number: 685 • 2012 ACR/ARHP Annual Meeting
Using a Library of Synthetic Autoantigen Mimics to Discover Biomarkers of Systemic Lupus Erythematosus
Akshai Lakhanpal¹, Jiexia Quan², Sayed Zaman¹, Nancy J. Olsen³ and David R. Karp², ¹Rheumatic Diseases Divsion, UT Southwestern Medical Center, Dallas, TX, ²Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ³Medicine, Penn State MS Hershey Medical Center, Hershey, PA
Background/Purpose: The natural history of systemic lupus erythematosus (SLE) is felt to evolve from a state of normal immunity to serologic autoimmunity and then…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.